High Throughput Genomics Appoints Jerry Zemaitis VP of Commercial Operations
News Aug 16, 2007
High Throughput Genomics, Inc. has announced the appointment of Jerry Zemaitis, Ph.D. to the position of vice president of commercial operations.
In this newly created position, Zemaitis will be responsible for forming strategic agreements with academic institutions, cultivating new business partnerships and establishing relationships with distributors in the U.S. and internationally.
Zemaitis joins HTG from Zeta Strategic Consulting, a consulting firm that specializes in business planning and marketing for life sciences and telecommunications companies, where he was founder and principal consultant.
“HTG’s assay technology has immense potential to accelerate the drug discovery process and bring new drugs to market faster,” said Jerry Zemaitis, Ph.D., vice president of commercial operations, HTG. “qNPA enables scientists to refocus on the biology and empowers them to make better decisions with higher confidence.”
Zemaitis earned a B.A. in biology from Rutgers, The State University of New Jersey and did graduate work in biochemistry at the University of Medicine and Dentistry of New Jersey.
Genome-wide association studies (GWAS) look at large populations to find genes that contribute to common, multi-gene traits like height or obesity. These comprehensive studies frequently turn up large numbers of tiny genetic variations that occur more often in people who are tall, obese, etc. So which genes should scientists investigate further?READ MORE
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.